检索结果-南通市图书馆

First-line camrelizumab(a PD-1 inhibitor)plus apatinib(an VEGFR-2 inhibitor)and chemotherapy for advanced gastric cancer(SPACE):a phase 1 study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2024年第4期9卷 1760-1767页

作者： Xiaofeng Chen Hao Xu Xiaobing Chen Tongpeng Xu Yitong Tian Deqiang Wang Fen Guo Kangxin Wang Guangfu Jin Xiao Li Rong Wang Fengyuan Li Yongbin Ding Jie Tang Yueyu Fang Jing Zhao Liang Liu Ling Ma Lijuan Meng Zhiguo Hou Rongrong Zheng Yang Liu Ni Guan Bei Zhang Shuang Tong Shiqing Chen Xing Li Yongqian Shu department of oncology The First Affiliated Hospital with Nanjing Medical UniversityNanjingChina Gusu School Nanjing medical UniversitySuzhouChina Jiangsu Key Lab of Cancer Biomarkers Prevention and TreatmentCollaborative Innovation Center for Cancer Personalized MedicineNanjing Medical UniversityNanjingChina department of General surgery The First Affiliated Hospital with Nanjing Medical UniversityNanjingChina department of oncology Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhouChina Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer&Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer ZhengzhouChina department of oncology Digestive Disease Institute&Cancer Institute of Jiangsu UniversityAffiliated Hospital of Jiangsu UniversityZhenjiangChina department of oncology Suzhou Hospital of Nanjing Medical UniversitySuzhouChina department of oncology Nanjing PuKou People’s HospitalNanjingChina department of Epidemiology School of Public HealthNanjing Medical UniversityNanjingChina department of Pathology The First Affiliated Hospital with Nanjing Medical UniversityNanjingChina department of general surgery Jurong Branch hospital of Jiangsu Province People HospitalJurongChina department of Medical oncology Liyang People’s HospitalLiyangChina department of radiology Nanjing PuKou People’s HospitalNanjingChina Jiangsu Hengrui Pharmaceuticals ShanghaiChina department of Medical Affairs 3D Medicines Inc.ShanghaiChina Shanghai OrigiMed Co. Ltd.ShanghaiChina

Patients with advanced gastric cancer typically face a grim *** phase 1a(dose escalation)and phase 1b(dose expansion)study investigated safety and efficacy of first-line camrelizumab plus apatinib and chemotherapyfor advanced gastric or gastroesophageal junction *** primary endpoints included maximum tolerated dose(MTD)in phase 1a and objective response rate(ORR)across phase 1a and *** 1a tested three dose regimens of camrelizumab,apatinib,oxaliplatin,and *** regimen 1:camrelizumab 200 mg on day 1,apatinib 250 mg every other day,oxaliplatin 100 mg/m^(2) on day 1,and S-140 mg twice a day on days *** regimen 2:same as dose regimen 1,but oxaliplatin 130mg/*** regimen3:same as dose regimen 2,but apatinib 250 mg ***-four patients were included(9 in phase 1a,25 in phase 1b).No dose-limiting toxicities occurred so no MTD was *** 3 was set for the recommended phase 2 doses and administered in phase *** confrmed ORR was 76.5%(95%CI 58.8-89.3).The median progression-free survival was 8.4 months(95%CI 5.9-not evaluable[NE]),and the median overall survival(OS)was not mature(11.6-NE).Ten patients underwent surgery after treatment and the multidisciplinary team *** 24 patients without surgery,the median OS was 19.6 months(7.8-NE).Eighteen patients(52.9%)developed grade≥3 treatment-emergent adverse *** plus apatinib and chemotherapy showed favorable clinical outcomes and manageable safety for untreated advanced gastric cancer(ChiCTR2000034109).

关键词： regimen cancer doses

IMpower210:A phase Ⅲ study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2024年第2期36卷 103-113页

作者： Yi-Long Wu Shun Lu Gongyan Chen Jianxing He Jifeng Feng Yiping Zhang Liyan Jiang Hongming Pan Jianhua Chang Jian Fang Amy Cai Lilian Bu Jane Shi Jinjing Xia Guangdong Lung Cancer Institute Guangdong Provincial Key Laboratory of Translational Medicine in Lung CancerGuangdong Provincial People's Hospital&Guangdong Academy of Medical SciencesSouthern Medical UniversityGuangzhou 510080China Shanghai Lung Cancer Center Shanghai Chest HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200025China department of Respiration Harbin Cancer HospitalHarbin Medical UniversityHarbin 150081China department of Thoracic oncology and Surgery the First Affliated Hospital of Guangzhou Medical UniversityGuangzhou 510120China department of Medical oncology Jiangsu Cancer HospitalNanjing 210009China department of Medical oncology Zhejiang Cancer HospitalHangzhou 330022China department of Pulmonary Medicine Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030China department of Medical oncology Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou 310016China department of Medical oncology Shenzhen HospitalCancer Hospital of Chinese Academy of Medical SciencesShenzhen 518116China department of Thoracic oncology Beijing Cancer HospitalBeijing 100142China Product Development Shanghai Roche Pharmaceutical LtdShanghai 201203China

Objective: IMpower210(NCT02813785) explored the efficacy and safety of single-agent atezolizumab *** as second-line treatment for advanced non-small cell lung cancer(NSCLC) in East Asian ***: Key eligibility criteria for this phase Ⅲ, open-label, randomized study included age ≥18 years;histologically documented advanced NSCLC per the Union for International Cancer Control/American Joint Committee on Cancer staging system(7th edition);Eastern Cooperative oncology Group performance status of 0 or 1;and disease progression following platinum-based chemotherapy for advanced or metastatic NSCLC. Patients were randomized 2:1 to receive either atezolizumab(1,200 mg) or docetaxel(75 mg/m^(2)). The primary study endpoint was overall survival(OS) in the intention-to-treat(ITT) population with wild-type epidermal growth factor receptor expression(ITT EGFR-WT) and in the overall ITT ***: Median OS in the ITT EGFR-WT population(n=467) was 12.3 [95% confidence interval(95% CI),10.3-13.8] months in the atezolizumab arm(n=312) and 9.9(95% CI, 7.8-13.9) months in the docetaxel arm[n=155;stratified hazard ratio(HR), 0.82;95% CI, 0.66-1.03]. Median OS in the overall ITT population was 12.5(95% CI, 10.8-13.8) months with atezolizumab treatment and 11.1(95% CI, 8.4-14.2) months(n=377) with docetaxel treatment(n=188;stratified HR, 0.87;95% CI, 0.71-1.08). Grade 3/4 treatment-related adverse events(TRAEs) occurred in 18.4% of patients in the atezolizumab arm and 50.0% of patients in the docetaxel ***: IMpower210 did not meet its primary efficacy endpoint of OS in the ITT EGFR-WT or overall ITT populations. Atezolizumab was comparatively more tolerable than docetaxel, with a lower incidence of grade3/4 TRAEs.

关键词： Atezolizumab East Asia non-small cell lung cancer programmed death-ligand 1 inhibitors monoclonal antibody

Cardiotoxicity induced by fluoropyrimidine drugs in the treatment of gastrointestinal tumors

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal oncology 2024年第2期16卷 251-254页

作者： Mo-Wei Kong Feng-Di Sun Zhen-Ying Pei Li Xu Ze-Bi Wang Yan Chen Shu-Qing Tang Ting-Fang Yang Guo-Xiang He department of Cardiology Guiqian International General HospitalGuiyang 550018Guizhou ProvinceChina department of oncology Guiqian International General HospitalGuiyang 550018Guizhou ProvinceChina

In this editorial,we review the article published in World J Gastrointest Oncol 2019,11:*** specifically focus on the occurrence,clinical characteristics,and risk factors of fluoropyrimidine drug-related cardiotoxicity in patients with gastrointestinal *** significant advancements in diagnostic and therapeutic techniques that have reduced mortality rates associated with digestive system tumors,the incidence and mortality rates of treatment-related car-diotoxicity have been increasing,severely impacting the survival and prognosis of cancer *** drugs are widely used as antimetabolites in the treatment of malignant tumors,including gastrointestinal tumors,and they represent the second largest class of drugs associated with ***,there is often a lack of awareness or understanding regarding their cardiotoxic effects and associated risks.

关键词： Cardiotoxicity Gastrointestinal tumors Risk factors Fluoropyrimidine Chest pain

Relationship between visceral obesity and prognosis in patients with stage IVB cervical cancer receiving radiotherapy and chemotherapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Pathogenesis and Therapy 2024年第3期2卷 180-186页

作者： Chao Ji Silin Liu Che Wang Jie Chen Jin Wang Xinyue Zhang Jinlu Ma Mengjiao Cai department of Radiation oncology The First Affiliated Hospital of Xi'an Jiaotong UniversityXi'anShaanxi 710061China

Background:Concurrent chemoradiotherapy is the preferred treatment for stage IVB cervical cancer;however,some patients experience a poor *** prognostic significance of body composition indicators,including visceral obesity,has been extensively investigated in patients with *** study aimed to assess the impact of body composition indicators,specifically pretreatment fat content,on the survival outcomes of patients with stage IVB cervical ***:We retrospectively analyzed clinical information from patients diagnosed with stage IVB cervical cancer between 2010 and *** measured visceral obesity(visceral-to-subcutaneous adipose tissue area ratio[VSR])and skeletal muscle index(SMI)on pretreatment computed tomography(CT)*** evaluated the impact of these body composition parameters on the prognosis of patients with cervical ***:Overall,116 patients were included,81 of whom had complete clinical and imaging *** on the cut-off values from X-tile analysis,we categorized patients into high and low VSR and SMI *** overall survival(OS)rate of patients with a high VSR was significantly higher than that of patients with a low VSR(P=0.022).Multivariate Cox regression analysis showed that a low VSR was an independent risk factor for the prognosis of patients with stage IVB cervical ***:Visceral obesity before radiotherapy and chemotherapy has a protective effect on the prognosis of patients with stage IVB cervical cancer,while low muscle index and VSR are associated with poor prognosis.

关键词： Cervical cancer Chemoradiotherapy Visceral obesity Prognosis

CD4^(+)T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cellular & Molecular Immunology 2024年第4期21卷 374-392页

作者： Xin Lei Daniël C.de Groot Marij J.P.Welters Tom de Wit Ellen Schrama Hans van Eenennaam Saskia J.Santegoets Timo Oosenbrug Annemarthe van der Veen Joris L.Vos Charlotte L.Zuur Noel F.C.C.de Miranda Heinz Jacobs Sjoerd H.van der Burg Jannie Borst Yanling Xiao department of Immunology Leiden University Medical CenterLeidenThe Netherlands Oncode Institute Leiden University Medical CenterLeidenThe Netherlands department of Tumor Biology and Immunology The Netherlands Cancer InstituteAmsterdamThe Netherlands department of Medical oncology Oncode InstituteLeiden University Medical CenterLeidenThe Netherlands IMMIOS B.V. OssThe Netherlands Division of Medical oncology The Netherlands Cancer InstituteAmsterdamThe Netherlands department of Otorhinolaryngology Leiden University Medical Center LeidenThe Netherlands department of Pathology Leiden University Medical CenterLeidenThe Netherlands

CD4^(+)T cells can"help"or"license" conventional type 1 dendritic cells(cDC1s)to induce CD8^(+)cytotoxic T lymphocyte(CTL)anticancer responses,as proven in mouse *** recently identified cDC1s with a transcriptomic imprint of CD4^(+)T-cell help,specifically in T-cell-infiltrated human cancers,and these cells were associated with a good prognosis and response to PD-1-targeting ***,we delineate the mechanism of cDC1 licensing by CD4^(+)T cells in *** CD4^(+)T cells produce IFNβvia the STING pathway,which promotes MHC-I antigen(cross-)presentation by cDC1s and thereby improves their ability to induce CTL anticancer *** cooperation with CD40 ligand(L),IFNβalso optimizes the costimulatory and other functions of cDC1s required for CTL response ***-I-producing CD4^(+)T cells are present in diverse T-cell-infiltrated cancers and likely deliver“help”signals to CTLs locally,according to their transcriptomic profile and colocalization with“helped/licensed”cDCs and tumor-reactive CD8^(+)T *** agreement with this scenario,the presence of IFN-I-producing CD4^(+)T cells in the TME is associated with overall survival and the response to PD-1 checkpoint blockade in cancer patients.

关键词： CD4^(+)T-cell help cDC1 licensing IFN-I signaling CD40 costimulation (cross-)presentation CTL priming Tumor control

Research status and hotspots of tight junctions and colorectal cancer:A bibliometric and visualization analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal oncology 2024年第8期16卷 3705-3715页

作者： Hui-Min Li Yin Liu Meng-Di Hao Xiao-Qing Liang Da-Jin Yuan Wen-Bin Huang Wen-Jie Li Lei Ding department of Gastrointestinal oncology Surgery Beijing Shijitan HospitalCapital Medical UniversityBeijing 100038China

BACKGROUND Colorectal cancer(CRC)is the third most common cancer worldwide and the second leading cause of cancer-related *** the past two decades,numerous researchers have provided important evidence regarding the role of tight junction(TJ)proteins in the occurrence and progression of *** causal relationship between the presence of specific TJ proteins and the development of CRC has also been *** the large number of publications in this field,a bibliometric study to review the current state of research and highlight the research trends and hotspots in this field has not yet been *** To analyze research on TJs and CRC,summarize the field’s history and current status,and predict future research *** We searched the Science Citation Index Expanded database for all literature on CRC and TJs from *** used bibliometrics to analyze the data of these papers,such as the authors,countries,institutions,and ***-authorship,co-citation,and co-occurrence analyses were the main methods of *** and VOSviewer were used to visualize the *** A total of 205 studies were ultimately *** number of publications on this topic has steadily increased since *** and the United States have made the largest contributions to this *** Research was the most prolific journal,publishing 8 articles,while the journal Oncogene had the highest average citation rate(68.33).Professor Dhawan P was the most prolific and cited author in this ***-occurrence analysis of keywords revealed that“tight junction protein expression”,“colorectal cancer”,“intestinal microbiota”,and“inflammatory bowel disease”had the highest frequency of occurrence,revealing the research hotspots and trends in this *** This bibliometric analysis evaluated the scope and trends of TJ proteins in CRC,providing valuable research perspectives and future directions for studying the connection between th

关键词： Colorectal cancer Tight junctions Bibliometric analysis Research trends Hot spots

Comprehensive genomic analysis of early and late-onset hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Genes & Diseases 2024年第4期11卷 77-81页

作者： Jialin Yang Chao Chen Song Wang Yaru Zhang Jiaohui Pang Yajun Wang Qiuxiang Ou Hao Jiang Juying Liu department of Radiation oncology Sichuan Cancer Hospital&InstituteSichuan Cancer CenterSchool of MedicineUniversity of Electronic Science and Technology of ChinaChengduSichuan 610041China Jinling Hospital Department of OncologyNanjing Medical UniversityNanjingJiangsu 210002China Geneseeq Research Institute Nanjing Geneseeq Technology Inc.NanjingJiangsu 210000China department of oncology Haian Hospital of Traditional Chinese MedicineHaianJiangsu 226600China Interventional Therapy department Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjingJiangsu 210009China

Hepatocellular carcinoma(HCC)is the major histologic type of primary liver cancer,accounting for approximately 75%of liver cancer cases.'Despite many advancements in its treatment,the prognosis and drug response of HCC patients are ***,there is an unmet clinical need to explore genomic aberrations underlying early-and lateonset HcC,which might facilitate drug discovery and provide personalized biomarker-driven treatment options for these patients.

关键词： patients prognosis cancer

Immune checkpoint inhibitor-associated gastritis:Patterns and management

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2024年第14期30卷 1941-1948页

作者： Jing Lin Zhong-Qiao Lin Shi-Cheng Zheng Yu Chen department of Medical oncology Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350000Fujian ProvinceChina Phase I Clinical Trial Ward Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350000Fujian ProvinceChina School of Basic Medical Sciences Fujian Medical UniversityFuzhou 350000Fujian ProvinceChina

Immune checkpoint inhibitors(ICIs)are widely used due to their effectiveness in treating various ***-related adverse events(irAEs)are defined as adverse effects resulting from ICI *** irAEs are a common type of irAEs characterized by intestinal side effects,such as diarrhea and colitis,which may lead to the cessation of *** irAE gastritis is rarely reported,it may lead to serious complications such as ***,irAE gastritis is often difficult to identify early due to its diverse *** steroid hormones and immunosuppressants are commonly used to reverse irAEs,the best regimen and dosage for irAE gastritis remains *** addition,the risk of recurrence of irAE gastritis after the reuse of ICIs should be *** this editorial,strategies such as early identification,pathological diagnosis,mana-gement interventions,and immunotherapy rechallenge are discussed to enable clinicians to better manage irAE gastritis and improve the prognosis of these patients.

关键词： Immunotherapy Immune checkpoint inhibitor Immune-related adverse events Immune checkpoint inhibitor-related gastritis

Impact of different anastomosis methods on post-recurrence after intestinal resection for Crohn's disease:A meta-analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Surgery 2024年第4期16卷 1165-1175页

作者： Zheng-Zuo Wang Chun-Hua Zhao Hui Shen Gui-Ping Dai department of Anorectal Jiashan Hospital of Traditional Chinese MedicineJiaxing 314100Zhejiang ProvinceChina department of oncology Jiashan Hospital of Traditional Chinese MedicineJiaxing 314100Zhejiang ProvinceChina department of Gastroenterology Jiashan Hospital of Traditional Chinese MedicineJiaxing 314100Zhejiang ProvinceChina department of oncology The Second Hospital of JiaxingJiaxing 314000Zhejiang ProvinceChina

BACKGROUND Crohn's disease(CD)is a chronic inflammatory disease of the gastrointestinal tract,often requiring intestinal resection as a common ***,recurrence after surgery is *** anastomotic configuration after bowel resection appears to be associated with the recurrence of *** studies have suggested that the Kono-S anastomosis may help to reduce the recurrence ***,the results remain ***,evidence-based evidence is needed to prove the advantages of Kono-S *** To measure the influence of anastomosis techniques on the long-term relapse rate of CD by conducting a *** PubMed,Scopus,and Cochrane Library were searched until October 8,*** who underwent intestinal resection due to CD were *** intervention measures included Kono-S anastomosis,whereas the control group received traditional anastomosis such as end-to-end,end-to-side,and side-to-side *** randomized clinical trials and observational studies were *** primary outcome measures were hospital stay post-surgery,overall postoperative complication incidence,the proportion of Clavien-Dindo grade IIIa or higher,overall postoperative recurrence rate,and Rutgeerts *** From 2011 to 2023,six articles met the inclusion and exclusion *** results indicated that Kono-S anastomosis can reduce the hospital stay post-surgery of patients with CD[MD=-0.26,95%CI:-0.42 to-0.10,P=0.002]than other traditional anastomosis *** to other traditional anastomosis methods,Kono-S anastomosis can significantly reduce the total recurrence rate[MD=0.40,95%CI:0.17 to 0.98,P=0.05]and postoperative Rutgeerts score[MD=-0.81,95%CI:-0.96 to-0.66,P<0.001]in patients with ***,there is no significant disparity in the overall occurrence of postoperative complications and the proportion of Clavien-Dindo≥*** Kono-S anastomosis has the potential to expedite the recuperation of CD and di

关键词： Kono-S Crohn’s disease Traditional anastomosis Postoperative recurrence Meta-analysis